GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amarin Corp PLC (NAS:AMRN) » Definitions » Shiller PE Ratio

Amarin (Amarin) Shiller PE Ratio : (As of Apr. 28, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Amarin Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Amarin Shiller PE Ratio Historical Data

The historical data trend for Amarin's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amarin Shiller PE Ratio Chart

Amarin Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Amarin Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Amarin's Shiller PE Ratio

For the Drug Manufacturers - General subindustry, Amarin's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amarin's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amarin's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Amarin's Shiller PE Ratio falls into.



Amarin Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Amarin's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Amarin's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.02/120.1096*120.1096
=-0.020

Current CPI (Dec. 2023) = 120.1096.

Amarin Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.150 100.573 -0.179
201406 0.080 100.773 0.095
201409 -0.170 100.474 -0.203
201412 -0.110 99.576 -0.133
201503 -0.180 99.975 -0.216
201506 -0.350 100.573 -0.418
201509 -0.180 100.274 -0.216
201512 -0.120 99.676 -0.145
201603 -0.160 99.676 -0.193
201606 -0.070 101.072 -0.083
201609 -0.080 100.274 -0.096
201612 -0.100 99.676 -0.120
201703 -0.080 100.374 -0.096
201706 -0.050 100.673 -0.060
201709 -0.040 100.474 -0.048
201712 -0.080 100.075 -0.096
201803 -0.080 100.573 -0.096
201806 -0.120 101.072 -0.143
201809 -0.080 101.371 -0.095
201812 -0.110 100.773 -0.131
201903 -0.070 101.670 -0.083
201906 -0.010 102.168 -0.012
201909 -0.010 102.268 -0.012
201912 0.020 102.068 0.024
202003 -0.060 102.367 -0.070
202006 0.010 101.769 0.012
202009 -0.020 101.072 -0.024
202012 0.010 101.072 0.012
202103 -0.004 102.367 -0.005
202106 0.020 103.364 0.023
202109 -0.030 104.859 -0.034
202112 0.040 106.653 0.045
202203 -0.080 109.245 -0.088
202206 -0.180 112.734 -0.192
202209 -0.010 113.431 -0.011
202212 0.002 115.425 0.002
202303 -0.040 117.618 -0.041
202306 -0.040 119.611 -0.040
202309 -0.050 120.708 -0.050
202312 -0.020 120.110 -0.020

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Amarin  (NAS:AMRN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Amarin Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Amarin's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Amarin (Amarin) Business Description

Traded in Other Exchanges
Address
112-114 St Stephens Green, Iconic Offices, The Greenway, Block C Ardilaun Court, Dublin, IRL, D02 TD28
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its lead product includes Vascepa.
Executives
Steven B Ketchum officer: Chief Scientific Officer 2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
Patrick Holt director, officer: See Remarks C/O AMARIN CORPORATION, SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2 L2 D02 VK60
Oliver O'connor director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Paul Cohen director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Diane E. Sullivan director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Louis Iii Sterling director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Keith Horn director 204 STATE ROUTE 17B, P.O. BOX 5013, C/O MONTICELLO CASINO AND RACEWAY, MONTICELLO NY 12701
Patrice Eadon Bonfiglio director 488 HAVILAND ROAD, STAMFORD CT 06903
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Thomas Charles Reilly officer: SVP and CFO C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Aaron Berg officer: EVP, President US C/O AMARIN PHARMA, INC., 1430 ROUTE 206, BEDMINSTER NJ 07921
Karim Mikhail director, officer: President and CEO C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Murray Stewart director C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3